PureTech Health Announces Initial Topline Results From Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In Patients With r/r AML And High-Risk MDS

Benzinga · 1d ago

LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially registrational Phase 2 trial

Initial median overall survival of 13.2 months observed in the combination cohort at the proposed Phase 2 dose, exceeding expected late-line relapsed/refractory setting survival of <2.5 months; overall survival data at this dose continue to mature with final results expected in 1H 2026

Responses observed in patients with high-risk mutations, suggesting potential broad applicability

Further details to be shared at the 67th American Society of Hematology (ASH) Annual Meeting

PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Gallop Oncology, today announced initial topline results from the Phase 1b clinical trial evaluating LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, in patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The data demonstrated a favorable tolerability profile and strong efficacy, supporting the advancement of LYT-200 into a potentially registrational Phase 2 trial in AML. Additional details will be shared at the 67th American Society of Hematology (ASH) Annual Meeting on December 6th, 2025.